People · Operator
Named in public records as an officer, director or promoter · active 2023–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tectonic Therapeutic, Inc. | — | Biotechnology | Series D+ | $333.1M | $1.7B | 2025 |
| Morphic Holding, Inc. | — | Biotechnology | Series C | $200.6M | $1.5B | 2023 |
Praveen P. Tipirneni at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Praveen P. Tipirneni on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Timothy A. Springer | 2 | 4 |
| Kevin Bitterman | 1 | 15 |
| Amir Nashat | 1 | 14 |
| Bruce Booth | 1 | 12 |
| Joshua Resnick | 1 | 12 |
| Terry McGuire | 1 | 8 |
| Bruce Rogers | 1 | 7 |
| Ramy Farid | 1 | 5 |
| Scott Requadt | 1 | 5 |
| Vikas Goyal | 1 | 5 |
| Ian Clark | 1 | 5 |
| Robert Farrell | 1 | 4 |
| PHILLIP B. DONENBERG | 1 | 4 |
| Timothy Springer | 1 | 3 |
| Christopher Mason | 1 | 3 |
| Gustav Christensen | 1 | 2 |
| Andrew Kruse | 1 | 2 |
| Barbara Dalton | 1 | 2 |
| Joseph P Slattery | 1 | 2 |
| Norbert Bischofberger | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.